RZLT
NASDAQ · Biotechnology
Rezolute Inc
$4.72
-0.16 (-3.28%)
Open$4.91
Previous Close$4.88
Day High$4.91
Day Low$4.55
52W High$11.46
52W Low$1.07
Volume—
Avg Volume1.20M
Market Cap451.61M
P/E Ratio—
EPS$-0.81
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+267.6% upside
Current
$4.72
$4.72
Target
$17.35
$17.35
$11.58
$17.35 avg
$20.59
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 45.23M | 44.79M | 46.31M |
| Net Income | 4.09M | 3.84M | 4.53M |
| Profit Margin | 9.0% | 8.6% | 9.8% |
| EBITDA | 6.09M | 5.25M | 5.80M |
| Free Cash Flow | 2.47M | 3.54M | 3.43M |
| Rev Growth | +6.6% | +21.1% | +6.0% |
| Debt/Equity | 0.15 | 0.18 | 0.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |